Pharmaceuticals, Biotechnology and Life Sciences
Series B Proceeds will Advance XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA4) into the Clinic while Expanding Xilio’s Tumor-Selective Cytokine…
Series B Proceeds will Advance XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA4) into the Clinic while Expanding Xilio’s Tumor-Selective Cytokine…
Three-year deal will enable broader chemical exploration and accelerate advanced molecular modeling across internal and collaborative programs NEW YORK–(BUSINESS WIRE)–Schrödinger,…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid…
DURHAM, N.C.–(BUSINESS WIRE)–JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer…
DURHAM, N.C.–(BUSINESS WIRE)–JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer…
– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia…
— Q4 2019 net income was $0.07 per basic and diluted share and adjusted non-GAAP net income was $0.49 per…
— Q4 2019 net income was $0.07 per basic and diluted share and adjusted non-GAAP net income was $0.49 per…